Real-world data analysis of efficacy and survival after Lu-177 PSMA
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]
What is in the pipeline for nuclear medicine, globally?
In recent years, the nuclear medicine market has undergone many [...]
Oncidium foundation welcomes it’s Turkish Ambassador
Welcome Mr. Hasan Ulaş Özcan as an Oncidium foundation Ambassador [...]
Oncidium foundation is a corporate member of the SNMMI Value Initiative
The Oncidium foundation is a corporate member of the Society [...]
Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model
Joint radionuclide therapy and immunotherapy approach. The combination shows promising [...]
February 2021 – The Winter Newsletter is out!
Looking back at 2020 accomplishments, fundraising campaign, meeting the newcomers [...]
World Cancer Day 2021
Today, the Oncidium foundation unites its voice with the World [...]
Hopeful 2021!
This year has shown us more than ever the importance [...]
New Theranostic Approach reduces tumor volume and increases survival in NET’s study
Axis - Dec 16, 2020 According to new research published [...]